| NeurotensinNTR1 activator |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Neurotensin Dilution Calculator
calculate
Neurotensin Molarity Calculator
calculate
| Cas No. | 39379-15-2 | SDF | Download SDF |
| Chemical Name | (Z)-5-(((Z)-1-((6-amino-1-(2-((Z)-(((Z)-1-((1-(2-((Z)-(((Z)-1-(((Z)-1-((1-carboxy-3-methylbutyl)imino)-1-hydroxy-3-methylpentan-2-yl)imino)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)imino)(hydroxy)methyl)pyrrolidin-1-yl)-5-guanidino-1-oxopentan-2-yl)imino) | ||
| Canonical SMILES | CCC(C(/N=C(O)/C(/N=C(O)/C1CCCN1C(C(/N=C(O)/C(/N=C(O)/C2CCCN2C(C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C3CCC(O)=N3)CC(C)C)CC4=CC=C(O)C=C4)CCC(O)=O)CC(O)=N)CCCCN)=O)CCCNC(N)=N)CCCNC(N)=N)=O)CC5=CC=C(O)C=C5)/C(O)=N/C(C(O)=O)CC(C)C)C | ||
| Formula | C78H121N21O20 | M.Wt | 1672.94 |
| Solubility | Soluble to 0.70 mg/ml in sterile water | Storage | Desiccate at -20°C |
| Physical Appearance | White lyophilised solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
IC50: N/A
Neurotensin (NT) can activate the G protein-coupled receptor, the neurotensin receptor 1 (NTR1). NT, a 13-amino acid neuropeptide, expressed in the central nervous system, and the intestine, including ileum3 and colon.
Neurotensin receptor 1 (NTR1) is a G protein-coupled receptor (neurotensin, NT) with high affinity.
In vitro: Due to NT/NTR1 signaling potentiates expression of miR-133α, the mechanism of NT-regulated miR-133α expression and examining the role of miR-133α in intracellular NTR1 trafficking in human NCM460 colonocytes are very important. The negative transcription regulator (zinc finger E-box binding homeobox 1) is involved in NT-induced miR-133α upregulation. A binding target of miR-133α (silencing of miR-133α or overexpression of aftiphilin (AFTPH)) lowered NTR1 trafficking to plasma membrane in human colonocytes without affecting NTR1 internalization. AFTPH to early endosomes and the trans-Golgi network (TGN) were localized in unstimulated human colonic epithelial cells. NTR1 localization was reduced by AFTPH overexpression in early endosomes. At the same time, it also increased expression of proteins related to endosomes and the TGN trafficking pathway. NTR1 expression was increased by AFTPH overexpression and de-acidification of intracellular vesicles. These results suggest a novel mechanism of GPCR trafficking in human colonic epithelial cells accounts for why a microRNA, miR-133α regulates NTR1 trafficking through its downstream target AFTPH.
In vivo: So far, no study in vivo has been conducted.
Clinical trial: So far, no clinical study has been conducted.
Reference:[1]. Law IK, Jensen D, Bunnett NW, Pothoulakis C. Neurotensin-induced miR-133α expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. Sci Rep. 2016 Feb 23;6:22195.
